|
|
|||||||||
Departments of Radiology, Chest Surgery, and Pathology, International Medical Center of Japan, Tokyo, Japan
Correspondence: For correspondence or reprints contact: Toshihiko Hara, MD, PhD, Department of Radiology, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162, Japan.
ABSTRACT
99mC-choline and FDG are PET tracers used to visualize various malignancies. In this study, we compared their capabilities in detecting mediastinal lymph node metastasis originating from non-small cell lung cancer (NSCLC). Methods: Twenty-nine patients with biopsy-proven NSCLC were studied with PET. 99mC-choline PET and FDG PET were performed from 5 and 40 min, respectively, after injection of 370 MBq tracer. PET data were analyzed in terms of the standardized uptake value (SUV). After the PET study, the patients underwent lung resection and mediastinal lymph node dissection. The resected specimens were examined pathologically, and the PET data were analyzed in reference to the pathologic data. Results: With 99mC-choline, the SUV in metastasis was similar to the SUV in the primary tumor, where the similarity of the SUV was 100% allowing for a 40% difference. With FDG, small metastases were invisible on the PET image. The SUV of FDG in metastasis was much smaller than that in the primary tumor, and the similarity of the SUV was only 19% allowing for a 40% difference. When pathologic findings were used as standards, the sensitivities of 99mC-choline PET and FDG PET in detecting mediastinal lymph node metastasis were 100% and 75%, respectively. Conclusion: 99mC-choline PET was very effective in detecting lymph node metastases in the mediastinum originating from NSCLC, with a sensitivity of 100%. 99mC-choline PET promises to be useful not only before surgery but also after surgery.
Key Words: PET 99mC-choline FDG lung cancer staging
This article has been cited by other articles:
![]() |
M. Piert, H. Park, A. Khan, J. Siddiqui, H. Hussain, T. Chenevert, D. Wood, T. Johnson, R. B. Shah, and C. Meyer Detection of Aggressive Primary Prostate Cancer with 11C-Choline PET/CT Using Multimodality Fusion Techniques J. Nucl. Med., October 1, 2009; 50(10): 1585 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Leyton, G. Smith, Y. Zhao, M. Perumal, Q.-D. Nguyen, E. Robins, E. Arstad, and E. O. Aboagye [18F]Fluoromethyl-[1,2-2H4]-Choline: A Novel Radiotracer for Imaging Choline Metabolism in Tumors by Positron Emission Tomography Cancer Res., October 1, 2009; 69(19): 7721 - 7728. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamamoto, Y. Nishiyama, R. Kameyama, K. Okano, H. Kashiwagi, A. Deguchi, M. Kaji, and M. Ohkawa Detection of Hepatocellular Carcinoma Using 11C-Choline PET: Comparison with 18F-FDG PET J. Nucl. Med., August 1, 2008; 49(8): 1245 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Terauchi, U. Tateishi, T. Maeda, D. Kanou, H. Daisaki, Y. Moriya, N. Moriyama, and T. Kakizoe A Case of Colon Cancer Detected by Carbon-11 Choline Positron Emission Tomography/Computed Tomography: An Initial Report Jpn. J. Clin. Oncol., October 1, 2007; 37(10): 797 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Spaeth, M. T. Wyss, B. Weber, S. Scheidegger, A. Lutz, J. Verwey, I. Radovanovic, J. Pahnke, D. Wild, G. Westera, et al. Uptake of 18F-Fluorocholine, 18F-Fluoroethyl-L-Tyrosine, and 18F-FDG in Acute Cerebral Radiation Injury in the Rat: Implications for Separation of Radiation Necrosis from Tumor Recurrence J. Nucl. Med., November 1, 2004; 45(11): 1931 - 1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Buck, G. Glatting, and S. N. Reske Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker? J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276. [Full Text] [PDF] |
||||
![]() |
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 879 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hara, N. Kosaka, T. Suzuki, K. Kudo, and H. Niino Uptake Rates of 18F-Fluorodeoxyglucose and 11C-Choline in Lung Cancer and Pulmonary Tuberculosis: A Positron Emission Tomography Study Chest, September 1, 2003; 124(3): 893 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Pieterman, T. H. Que, P. H. Elsinga, J. Pruim, J. W.G. van Putten, A. T.M. Willemsen, W. Vaalburg, and H. J.M. Groen Comparison of 11C-Choline and 18F-FDG PET in Primary Diagnosis and Staging of Patients with Thoracic Cancer J. Nucl. Med., February 1, 2002; 43(2): 167 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hara, N. Kosaka, and H. Kishi Development of 18F-Fluoroethylcholine for Cancer Imaging with PET: Synthesis, Biochemistry, and Prostate Cancer Imaging J. Nucl. Med., February 1, 2002; 43(2): 187 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kotzerke, J. E. Gschwend, and B. Neumaier PET for Prostate Cancer Imaging: Still a Quandary or the Ultimate Solution? J. Nucl. Med., February 1, 2002; 43(2): 200 - 202. [Full Text] [PDF] |
||||
![]() |
T. R. DeGrado, R. E. Reiman, D. T. Price, S. Wang, and R. E. Coleman Pharmacokinetics and Radiation Dosimetry of 18F-Fluorocholine J. Nucl. Med., January 1, 2002; 43(1): 92 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hara 18F-Fluorocholine: A New Oncologic PET Tracer J. Nucl. Med., December 1, 2001; 42(12): 1815 - 1817. [Full Text] [PDF] |
||||
![]() |
C. O. Wong, H. J. Dworkin, T. Hara, K. Inagaki, N. Kosaka, and T. Morita Clinical Skills in Conducting Research Studies on Clinical Applications of Oncologic PET J. Nucl. Med., May 1, 2001; 42(5): 826a - 827. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |